Repurposing Siponimod for Alzheimer's Disease
NCT06639282
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Mild Alzheimer Disease
- MCI With Increased Risk for Alzheimer Disease
- Cognitive Impairment, Mild
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Last updated on ClinicalTrials.gov
- March 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- St. Joseph's Hospital and Medical Center · Phoenix, AZ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.